within Pharmacolibrary.Drugs.ATC.H;

model H01BB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.6983333333333334,
    adminDuration  = 600,
    adminMass      = 0.0001,
    adminCount     = 1,
    Vd             = 0.027,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Carbetocin is a synthetic long-acting analogue of oxytocin, used mainly for the prevention of uterine atony and postpartum hemorrhage following delivery by cesarean section. It acts as a uterotonic agent and is approved in various countries for use immediately after childbirth, particularly following cesarean delivery under anesthesia.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy postpartum women after intravenous administration of a single 100 mcg dose following cesarean section.</p><h4>References</h4><ol><li>Pan Sun, Hongzhi Xiao, Jianzhong Wang, Suxia Zhang, Xingyuan Cao,Pharmacokinetics and bioavailability of carbetocin after intravenous and intramuscular administration in cows and gilts.,Journal of veterinary pharmacology and therapeutics,2020<a href='https://pubmed.ncbi.nlm.nih.gov/31856330/'>https://pubmed.ncbi.nlm.nih.gov/31856330/</a></li><li>Desire N Onwochei, Neel Desai, Lawrence C Tsen,Uterotonics update.,Best practice & research. Clinical anaesthesiology,2024<a href='https://pubmed.ncbi.nlm.nih.gov/39764811/'>https://pubmed.ncbi.nlm.nih.gov/39764811/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end H01BB03;
